Skip to main content

. 1991 Nov;64(5):973–974. doi: 10.1038/bjc.1991.440

The clinical activity of cyproterone acetate in advanced ovarian carcinoma. A London Gynaecology Oncology Group Study.

P Thompson ¹, P Wilson ¹, R Osborne ¹, M Slevin ¹, F Wiltshaw ¹, P Blake ¹, P Harper ¹, R Coleman ¹, C Williams ¹, J Sweetenham ¹, et al.

PMCID: PMC1977484 PMID: 1834157

973

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Ford L. C., Berek J. S., Lagasse L. D., Hacker N. F., Heins Y., Esmailian F., Leuchter R. S., DeLange R. J. Estrogen and progesterone receptors in ovarian neoplasms. Gynecol Oncol. 1983 Jun;15(3):299–304. doi: 10.1016/0090-8258(83)90047-1. [DOI] [PubMed] [Google Scholar]
Hamilton T. C., Davies P., Griffiths K. Androgen and oestrogen binding in cytosols of human ovarian tumours. J Endocrinol. 1981 Sep;90(3):421–431. doi: 10.1677/joe.0.0900421. [DOI] [PubMed] [Google Scholar]
Holt J. A., Caputo T. A., Kelly K. M., Greenwald P., Chorost S. Estrogen and progestin binding in cytosols of ovarian adenocarcinomas. Obstet Gynecol. 1979 Jan;53(1):50–58. [PubMed] [Google Scholar]
Neumann F. Pharmacology and clinical use of antiandrogens: a short review. Ir J Med Sci. 1982 Mar;151(3):61–70. doi: 10.1007/BF02940148. [DOI] [PubMed] [Google Scholar]
Osborne R. J., Malik S. T., Slevin M. L., Harvey V. J., Spona J., Salzer H., Williams C. J. Tamoxifen in refractory ovarian cancer: the use of a loading dose schedule. Br J Cancer. 1988 Jan;57(1):115–116. doi: 10.1038/bjc.1988.22. [DOI] [PMC free article] [PubMed] [Google Scholar]
Rendina G. M., Donadio C., Giovannini M. Steroid receptors and progestinic therapy in ovarian endometrioid carcinoma. Eur J Gynaecol Oncol. 1982;3(3):241–246. [PubMed] [Google Scholar]
Shirey D. R., Kavanagh J. J., Jr, Gershenson D. M., Freedman R. S., Copeland L. J., Jones L. A. Tamoxifen therapy of epithelial ovarian cancer. Obstet Gynecol. 1985 Oct;66(4):575–578. [PubMed] [Google Scholar]
Slevin M. L., Harvey V. J., Osborne R. J., Shepherd J. H., Williams C. J., Mead G. M. A phase II study of tamoxifen in ovarian cancer. Eur J Cancer Clin Oncol. 1986 Mar;22(3):309–312. doi: 10.1016/0277-5379(86)90396-2. [DOI] [PubMed] [Google Scholar]
Slotman B. J., Rao B. R. Ovarian cancer (review). Etiology, diagnosis, prognosis, surgery, radiotherapy, chemotherapy and endocrine therapy. Anticancer Res. 1988 May-Jun;8(3):417–434. [PubMed] [Google Scholar]
Weiner S. A., Alberts D. S., Surwit E. A., Davis J., Grosso D. Tamoxifen therapy in recurrent epithelial ovarian carcinoma. Gynecol Oncol. 1987 Jun;27(2):208–213. doi: 10.1016/0090-8258(87)90294-0. [DOI] [PubMed] [Google Scholar]
Willcocks D., Toppila M., Hudson C. N., Tyler J. P., Baird P. J., Eastman C. J. Estrogen and progesterone receptors in human ovarian tumors. Gynecol Oncol. 1983 Oct;16(2):246–253. doi: 10.1016/0090-8258(83)90099-9. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES